Track record
Every buy, sell, and watch call I've published — scored against XBI, the biotech index.
As of Sep 18, 2026 · hypothetical editorial record, not investment advice
How to read this page
- Buy
- A buy call I published — Core = higher conviction.
- Spec buy
- A speculative buy — higher risk, smaller-size idea.
- Avoid
- A call to stay away — scored by the loss it sidestepped.
- Entry
- The first closing price after I published the call — if I posted after the 4pm ET close, that's the next session's close, since it's the first price you could actually have traded at.
- Now
- The latest available closing price.
- Return
- Percent change from Entry to Now (for avoids, the stock's move since the call).
- vs XBI
- XBI is the biotech index ETF. This is Return minus XBI's return over the same dates — the value added beyond just buying the index. For avoids, the loss saved vs holding XBI.
- Open / Closed
- Open = still live. Closed = realized; the return runs to the first close after I flipped the call. Where a buyout settled at a known cash price, I use that instead.
Top buy calls
| Call | Buy | Now | Return | vs XBI |
|---|---|---|---|---|
| ETON Eton Pharmaceuticals Buy | $18.22 | $55.50 | +204.6% | +181 |
| SYRE Spyre Therapeutics Buy | $33.47 | $90.25 | +169.6% | +138.6 |
| DFTX Definium Therapeutics Buy | $15.02 | $38.81 | +158.4% | +134.8 |
| DRTS Alpha Tau Medical Spec buy | $5.90 | $15.24 | +158.3% | +134.3 |
| CAPR Capricor Therapeutics Spec buy | $4.17 | $9.06 | +117.3% | +114.1 |
| TTRX Turn Therapeutics Spec buy | $6.42 | $14.94 | +132.7% | +110 |
| IBRX ImmunityBio Buy | $3.95 | $8.48 | +114.7% | +88.5 |
| HELP Cybin Spec buy | $6.61 | $12.37 | +87.1% | +88.1 |
| CMPS COMPASS Pathways Buy | $7.85 | $15.19 | +93.5% | +70.1 |
| CRDL Cardiol Therapeutics Spec buy | $1.02 | $1.88 | +83.8% | +60 |
What I told you to avoid
| Call | Since | Stock | Saved vs XBI |
|---|---|---|---|
| RVPH Reviva Pharmaceuticals Avoid | Jan 26, 2026 | -92.1% | +114.7 |
| LGVN Longeveron Avoid | May 11, 2026 | -70.3% | +86.6 |
| APVO Aptevo Therapeutics Avoid | Jun 16, 2026 | -59.5% | +75.3 |
| NRSN NeuroSense Therapeutics Avoid | Jul 13, 2026 | -56.5% | +57.4 |
| VNDA Vanda Pharmaceuticals Avoid | Feb 17, 2026 | -17.3% | +43 |
| MRKR Marker Therapeutics Avoid | Mar 16, 2026 | -16.3% | +42.8 |
| OTLK Outlook Therapeutics Avoid | Jul 27, 2026 | -38.7% | +42.8 |
| ELTX Elicio Therapeutics Avoid | Jul 6, 2026 | -42.6% | +40.1 |
Calls that paid off
Buy calls I closed in the green — including takeouts. Entry → exit, realized.
| Call | Bought | Exited | Return | vs XBI |
|---|---|---|---|---|
| FBRX Forte Biosciences Acquired | Apr 6, 2026 | Jul 28, 2026 | +189.9% | +173.6 |
| CRNX Crinetics Pharmaceuticals Acquired | Apr 2, 2026 | Jul 7, 2026 | +124.4% | +97.3 |
| ATAI Atai Beckley Acquired | Dec 24, 2025 | Jul 17, 2026 | +72.3% | +50.2 |
| APGE Apogee Therapeutics Acquired | May 5, 2026 | Jun 23, 2026 | +59.5% | +49.6 |
| CNTA Centessa Pharmaceuticals plc Acquired | Mar 16, 2026 | Jun 23, 2026 | +43.2% | +24.4 |
| QURE uniQure Spec buy | Jun 18, 2026 | Jun 23, 2026 | +5.9% | +1.4 |
| ENTA Enanta Pharmaceuticals Buy | Feb 17, 2026 | Jul 6, 2026 | +4.7% | -24.5 |
Every call
| Call | Entry | Now | Return | vs XBI | Status | Opened |
|---|---|---|---|---|---|---|
| ETON Eton Pharmaceuticals Buy | $18.22 | $55.50 | +204.6% | +181 | Open | Feb 19, 2026 |
| FBRX Forte Biosciences Buy | $26.44 | $76.65 | +189.9% | +173.6 | Closed Jul 28, 2026 | Apr 6, 2026 |
| SYRE Spyre Therapeutics Buy | $33.47 | $90.25 | +169.6% | +138.6 | Open | Dec 18, 2025 |
| DFTX Definium Therapeutics Buy | $15.02 | $38.81 | +158.4% | +134.8 | Open | Jan 14, 2026 |
| DRTS Alpha Tau Medical Spec buy | $5.90 | $15.24 | +158.3% | +134.3 | Open | Jan 7, 2026 |
| RVPH Reviva Pharmaceuticals Avoid | $6.04 | $0.48 | -92.1% | +114.7 | Open | Jan 26, 2026 |
| CAPR Capricor Therapeutics Spec buy | $4.17 | $9.06 | +117.3% | +114.1 | Open | Aug 4, 2026 |
| TTRX Turn Therapeutics Spec buy | $6.42 | $14.94 | +132.7% | +110 | Open | Jun 2, 2026 |
| CRNX Crinetics Pharmaceuticals Buy | $37.23 | $83.53 | +124.4% | +97.3 | Closed Jul 7, 2026 | Apr 2, 2026 |
| GOSS Gossamer Bio Avoid | $34.29 | $14.00 | -59.2% | +88.9 | Closed Aug 24, 2026 | Mar 2, 2026 |
| IBRX ImmunityBio Buy | $3.95 | $8.48 | +114.7% | +88.5 | Open | Jan 15, 2026 |
| HELP Cybin Spec buy | $6.61 | $12.37 | +87.1% | +88.1 | Open | Jun 30, 2026 |
| LGVN Longeveron Avoid | $8.38 | $2.49 | -70.3% | +86.6 | Open | May 11, 2026 |
| APVO Aptevo Therapeutics Avoid | $4.54 | $1.84 | -59.5% | +75.3 | Open | Jun 16, 2026 |
| CMPS COMPASS Pathways Buy | $7.85 | $15.19 | +93.5% | +70.1 | Open | Feb 23, 2026 |
| ACTU Actuate Therapeutics Avoid | $6.49 | $2.89 | -55.5% | +62.2 | Closed May 12, 2026 | Jan 7, 2026 |
| CRDL Cardiol Therapeutics Spec buy | $1.02 | $1.88 | +83.8% | +60 | Open | Mar 2, 2026 |
| NRSN NeuroSense Therapeutics Avoid | $14.60 | $6.35 | -56.5% | +57.4 | Open | Jul 13, 2026 |
| GHRS GH Research Buy | $15.75 | $28.26 | +79.4% | +54.3 | Open | Jan 20, 2026 |
| ADAG Adagene Spec buy | $1.84 | $3.31 | +79.9% | +50.9 | Open | Jan 2, 2026 |
| ATAI Atai Beckley Spec buy | $4.19 | $7.22 | +72.3% | +50.2 | Closed Jul 17, 2026 | Dec 24, 2025 |
| APGE Apogee Therapeutics Buy | $83.29 | $132.88 | +59.5% | +49.6 | Closed Jun 23, 2026 | May 5, 2026 |
| CGEM Cullinan Therapeutics Buy | $12.57 | $21.08 | +67.7% | +48.6 | Open | Jan 22, 2026 |
| ABSI Absci Buy | $5.90 | $9.65 | +63.6% | +47.2 | Open | May 8, 2026 |
| CING Cingulate Avoid | $5.84 | $5.09 | -12.8% | +45.4 | Closed Aug 14, 2026 | Mar 30, 2026 |
| PCSA Processa Pharmaceuticals Avoid | $2.87 | $2.04 | -28.9% | +43.6 | Closed Jul 30, 2026 | Apr 13, 2026 |
| VNDA Vanda Pharmaceuticals Avoid | $6.20 | $5.13 | -17.3% | +43 | Open | Feb 17, 2026 |
| MRKR Marker Therapeutics Avoid | $1.41 | $1.18 | -16.3% | +42.8 | Open | Mar 16, 2026 |
| OTLK Outlook Therapeutics Avoid | $1.06 | $0.65 | -38.7% | +42.8 | Open | Jul 27, 2026 |
| TVTX Travere Therapeutics Buy | $40.29 | $62.76 | +55.8% | +42 | Open | Apr 20, 2026 |
| NRIX Nurix Therapeutics Buy | $15.91 | $25.44 | +59.9% | +41.2 | Open | Apr 13, 2026 |
| ELTX Elicio Therapeutics Avoid | $3.29 | $1.89 | -42.6% | +40.1 | Open | Jul 6, 2026 |
| CLYM Climb Bio Buy | $8.78 | $14.05 | +60% | +38.4 | Open | Apr 29, 2026 |
| PHIO Phio Pharmaceuticals Avoid | $1.32 | $1.03 | -22% | +36.8 | Open | Apr 15, 2026 |
| IRD Opus Genetics Spec buy | $3.71 | $5.18 | +39.6% | +36.4 | Open | Aug 4, 2026 |
| ORKA Oruka Therapeutics Buy | $63.18 | $94.96 | +50.3% | +34.9 | Open | May 13, 2026 |
| ACTU Actuate Therapeutics Avoid | $1.40 | $0.98 | -29.9% | +33.8 | Open | Jul 20, 2026 |
| REPL Replimune Group Buy | $9.00 | $13.07 | +45.2% | +27.8 | Open | Jun 1, 2026 |
| OVID Ovid Therapeutics Spec buy | $1.81 | $2.69 | +48.6% | +26.7 | Open | Jan 27, 2026 |
| EVMN Evommune Avoid | $13.29 | $9.65 | -27.4% | +26.4 | Open | Jun 30, 2026 |
| VOR Vor Biopharma Spec buy | $14.63 | $21.40 | +46.3% | +26.4 | Open | May 15, 2026 |
| CNTA Centessa Pharmaceuticals plc Buy | $28.29 | $40.50 | +43.2% | +24.4 | Closed Jun 23, 2026 | Mar 16, 2026 |
| SPRB Spruce Biosciences Buy | $41.60 | $53.05 | +27.5% | +22.9 | Open | Jul 28, 2026 |
| PMVP PMV Pharmaceuticals Spec buy | $1.29 | $1.50 | +16.3% | +20.4 | Open | Sep 1, 2026 |
| IMVT Immunovant Buy | $26.08 | $36.95 | +41.7% | +18.6 | Open | Feb 2, 2026 |
| KAPA Kairos Pharma Avoid | $2.17 | $1.73 | -20.3% | +18.2 | Open | Aug 18, 2026 |
| MDNAF Medicenna Therapeutics Avoid | $0.40 | $0.32 | -20% | +17.6 | Closed May 20, 2026 | May 14, 2026 |
| QNRX Quoin Pharmaceuticals Spec buy | $6.22 | $7.06 | +13.5% | +17.1 | Open | Aug 31, 2026 |
| CUE Cue Biopharma Spec buy | $26.91 | $37.05 | +37.7% | +17 | Open | Jun 3, 2026 |
| IXHL Incannex Healthcare Avoid | $3.31 | $3.64 | +10% | +16.5 | Open | Mar 16, 2026 |
| CGON CG Oncology Buy | $53.81 | $74.62 | +38.7% | +16.3 | Open | Jan 23, 2026 |
| KYMR Kymera Therapeutics Buy | $87.35 | $117.75 | +34.8% | +15.9 | Open | Apr 9, 2026 |
| EXEL Exelixis Spec buy | $41.36 | $58.36 | +41.1% | +15.5 | Open | Jan 30, 2026 |
| HELP Cybin Avoid | $5.52 | $4.32 | -21.7% | +15.2 | Closed Mar 30, 2026 | Mar 9, 2026 |
| ARDX Ardelyx Avoid | $4.00 | $3.42 | -14.5% | +14.1 | Open | Aug 7, 2026 |
| ZYME Zymeworks Buy | $23.54 | $26.57 | +12.9% | +13.3 | Open | Aug 7, 2026 |
| XNCR Xencor Spec buy | $21.49 | $24.72 | +15% | +11.6 | Open | Jul 30, 2026 |
| CYDY CytoDyn Avoid | $0.37 | $0.32 | -13.5% | +11.1 | Closed Apr 27, 2026 | Apr 21, 2026 |
| VSTM Verastem Spec buy | $6.74 | $7.44 | +10.4% | +10.8 | Open | Aug 7, 2026 |
| UNCY Unicycive Therapeutics Avoid | $5.13 | $4.80 | -6.4% | +10.6 | Open | Jul 27, 2026 |
| PYPD PolyPid Spec buy | $4.78 | $5.21 | +9% | +9.1 | Open | Aug 13, 2026 |
| CBIO Crescent Biopharma Buy | $15.11 | $16.89 | +11.8% | +8.7 | Open | Jul 16, 2026 |
| KURA Kura Oncology Buy | $9.22 | $11.73 | +27.2% | +7.3 | Open | May 15, 2026 |
| SGMT Sagimet Biosciences Spec buy | $8.75 | $11.09 | +26.7% | +7.3 | Open | Apr 28, 2026 |
| ZBIO Zenas BioPharma Spec buy | $29.51 | $31.50 | +6.7% | +7.2 | Open | Aug 14, 2026 |
| SLDB Solid Biosciences Spec buy | $8.39 | $8.91 | +6.2% | +6.6 | Open | Aug 7, 2026 |
| CHRS Coherus Oncology Spec buy | $1.26 | $1.35 | +6.7% | +5.3 | Open | Aug 6, 2026 |
| XERS Xeris Biopharma Spec buy | $7.93 | $8.20 | +3.4% | +3.8 | Open | Aug 7, 2026 |
| NGNE Neurogene Spec buy | $31.45 | $32.09 | +2% | +3 | Open | Jun 30, 2026 |
| CRVO CervoMed Avoid | $2.44 | $2.86 | +17.2% | +2 | Closed Aug 10, 2026 | Jun 11, 2026 |
| ACRS Aclaris Therapeutics Buy | $4.47 | $5.50 | +23% | +1.5 | Open | Apr 29, 2026 |
| GRCE Grace Therapeutics Avoid | $2.16 | $2.10 | -2.8% | +1.4 | Closed Apr 28, 2026 | Apr 27, 2026 |
| QURE uniQure Spec buy | $46.29 | $49.04 | +5.9% | +1.4 | Closed Jun 23, 2026 | Jun 18, 2026 |
| KPRX Kiora Pharmaceuticals Spec buy | $2.32 | $2.76 | +19% | +1.2 | Open | Apr 27, 2026 |
| IMMX Immix Biopharma Buy | $10.66 | $12.50 | +17.3% | +1.1 | Open | May 12, 2026 |
| BEAM Beam Therapeutics Spec buy | $25.18 | $24.95 | -0.9% | +0.8 | Open | Sep 9, 2026 |
| CYDY CytoDyn Avoid | $0.22 | $0.21 | -4.5% | +0.5 | Open | Sep 1, 2026 |
| PEPG PepGen Spec buy | $2.85 | $2.85 | 0% | +0.4 | Open | Aug 7, 2026 |
| PTGX Protagonist Therapeutics Buy | $147.75 | $143.00 | -3.2% | +0.3 | Open | Aug 31, 2026 |
| BMEA Biomea Fusion Spec buy | $1.53 | $1.83 | +19.6% | +0.1 | Open | Apr 28, 2026 |
| IMCR Immunocore Spec buy | $32.00 | $32.00 | 0% | 0 | Open | Sep 18, 2026 |
| RNAC Cartesian Therapeutics Buy | $6.93 | $8.03 | +15.9% | -0.7 | Open | May 27, 2026 |
| ARTV Artiva Biotherapeutics Spec buy | $7.27 | $8.61 | +18.4% | -0.9 | Open | Jun 9, 2026 |
| ONCY Oncolytics Biotech Avoid | $0.77 | $0.77 | 0% | -1 | Open | Sep 17, 2026 |
| GRCE Grace Therapeutics Spec buy | $2.12 | $2.11 | -0.5% | -1.9 | Open | Aug 6, 2026 |
| CLDX Celldex Therapeutics Buy | $33.86 | $38.24 | +12.9% | -2.8 | Open | Apr 16, 2026 |
| BLTE Belite Bio Spec buy | $178.94 | $170.96 | -4.5% | -2.8 | Open | Aug 12, 2026 |
| ARVN Arvinas Spec buy | $8.40 | $8.29 | -1.3% | -3.7 | Open | Aug 5, 2026 |
| AUTL Autolus Therapeutics Spec buy | $1.95 | $1.94 | -0.5% | -3.7 | Open | Aug 4, 2026 |
| JANX Janux Therapeutics Buy | $14.11 | $16.59 | +17.6% | -4 | Open | Apr 29, 2026 |
| ADCT ADC Therapeutics Avoid | $1.01 | $1.05 | +4% | -4.4 | Open | Aug 14, 2026 |
| AKTS Aktis Oncology Buy | $19.73 | $21.88 | +10.9% | -5.3 | Open | May 12, 2026 |
| PRQR ProQR Therapeutics Spec buy | $1.94 | $1.83 | -5.7% | -5.6 | Open | Sep 10, 2026 |
| INBX Inhibrx Biosciences Spec buy | $122.26 | $109.35 | -10.6% | -5.9 | Open | Sep 3, 2026 |
| PMN ProMIS Neurosciences Spec buy | $14.06 | $14.01 | -0.4% | -6.3 | Open | Jul 29, 2026 |
| BCTX BriaCell Therapeutics Avoid | $3.31 | $4.21 | +27.2% | -6.5 | Open | Jun 3, 2026 |
| FBIO Fortress Biotech Spec buy | $2.27 | $2.51 | +10.6% | -7.2 | Open | Apr 27, 2026 |
| SABS SAB Biotherapeutics Spec buy | $3.67 | $3.51 | -4.2% | -7.3 | Open | Jul 16, 2026 |
| PCSA Processa Pharmaceuticals Spec buy | $2.04 | $1.96 | -3.9% | -7.4 | Open | Jul 30, 2026 |
| TENX Tenax Therapeutics Avoid | $1.62 | $1.80 | +11.1% | -7.7 | Closed Sep 1, 2026 | Aug 11, 2026 |
| NRXP NRX Pharmaceuticals Spec buy | $3.03 | $3.32 | +9.6% | -8.2 | Open | Apr 27, 2026 |
| AMLX Amylyx Pharmaceuticals Spec buy | $38.60 | $32.41 | -16% | -8.5 | Open | Aug 19, 2026 |
| VIR Vir Biotechnology Buy | $8.99 | $10.60 | +17.9% | -8.6 | Open | Mar 25, 2026 |
| ALLO Allogene Therapeutics Spec buy | $1.79 | $1.69 | -5.6% | -8.7 | Open | Jul 16, 2026 |
| AGMB Agomab Therapeutics Spec buy | $12.68 | $12.17 | -4% | -8.7 | Open | Jun 24, 2026 |
| ENTA Enanta Pharmaceuticals Spec buy | $13.50 | $12.20 | -9.6% | -8.8 | Open | Aug 12, 2026 |
| SNDX Syndax Pharmaceuticals Buy | $20.56 | $17.62 | -14.3% | -10 | Open | Sep 4, 2026 |
| OMER Omeros Buy | $15.71 | $17.87 | +13.7% | -11.6 | Open | Dec 26, 2025 |
| VERA Vera Therapeutics Buy | $31.27 | $34.00 | +8.7% | -12 | Open | Jun 3, 2026 |
| LEGN Legend Biotech Spec buy | $20.65 | $17.61 | -14.7% | -13 | Open | Aug 12, 2026 |
| ZNTL Zentalis Pharmaceuticals Spec buy | $3.83 | $3.11 | -18.7% | -13.3 | Open | Aug 21, 2026 |
| SMMT Summit Therapeutics Buy | $15.94 | $17.85 | +12% | -13.6 | Open | Feb 20, 2026 |
| ADMA Adma Biologics Avoid | $9.16 | $10.06 | +9.8% | -13.7 | Closed Aug 6, 2026 | Jul 6, 2026 |
| CRVS Corvus Pharmaceuticals Buy | $11.50 | $12.56 | +9.2% | -14.4 | Open | May 19, 2026 |
| LGVN Longeveron Spec buy | $8.88 | $8.38 | -5.6% | -14.4 | Closed May 11, 2026 | Mar 16, 2026 |
| SRPT Sarepta Therapeutics Spec buy | $17.79 | $20.11 | +13% | -14.5 | Open | Feb 13, 2026 |
| NVCT Nuvectis Pharma Spec buy | $24.48 | $22.00 | -10.1% | -14.8 | Open | Jun 24, 2026 |
| RCUS Arcus Biosciences Spec buy | $24.69 | $25.24 | +2.2% | -15.2 | Open | Jun 4, 2026 |
| BCTX BriaCell Therapeutics Spec buy | $4.47 | $3.76 | -15.9% | -15.6 | Closed Feb 23, 2026 | Feb 2, 2026 |
| NBP NovaBridge Biosciences Spec buy | $1.95 | $1.60 | -17.9% | -17 | Open | Jun 30, 2026 |
| LENZ LENZ Therapeutics Spec buy | $5.04 | $4.07 | -19.2% | -17.6 | Open | Aug 12, 2026 |
| SION Sionna Therapeutics Avoid | $5.10 | $5.96 | +16.9% | -17.7 | Open | Aug 11, 2026 |
| MPLT MapLight Therapeutics Spec buy | $12.92 | $10.92 | -15.5% | -17.9 | Open | Aug 5, 2026 |
| HELP Cybin Spec buy | $6.73 | $5.52 | -18% | -18.1 | Closed Mar 9, 2026 | Feb 23, 2026 |
| VRCA Verrica Pharmaceuticals Spec buy | $5.69 | $4.45 | -21.8% | -18.3 | Open | Aug 28, 2026 |
| ALLO Allogene Therapeutics Spec buy | $2.25 | $2.07 | -8% | -18.5 | Closed Jun 23, 2026 | Apr 27, 2026 |
| OCS Oculis Holding Spec buy | $11.99 | $10.14 | -15.4% | -18.6 | Open | Aug 4, 2026 |
| GERN Geron Spec buy | $1.57 | $1.30 | -17.2% | -18.6 | Open | Aug 6, 2026 |
| DYN Dyne Therapeutics Buy | $16.58 | $17.11 | +3.2% | -21.9 | Open | Jan 20, 2026 |
| SANA Sana Biotechnology Spec buy | $3.26 | $3.10 | -4.9% | -22.7 | Open | Apr 27, 2026 |
| MDNAF Medicenna Therapeutics Spec buy | $0.32 | $0.30 | -5.3% | -22.9 | Open | May 26, 2026 |
| CCCC C4 Therapeutics Buy | $3.68 | $3.39 | -7.9% | -23.2 | Open | May 13, 2026 |
| ARTV Artiva Biotherapeutics Spec buy | $10.60 | $7.84 | -26% | -23.7 | Closed May 20, 2026 | May 11, 2026 |
| ENTA Enanta Pharmaceuticals Buy | $13.86 | $14.51 | +4.7% | -24.5 | Closed Jul 6, 2026 | Feb 17, 2026 |
| ERAS Erasca Spec buy | $11.56 | $9.11 | -21.2% | -24.6 | Closed Apr 29, 2026 | Feb 11, 2026 |
| RCKT Rocket Pharmaceuticals Buy | $3.48 | $3.37 | -3.2% | -24.7 | Open | Apr 29, 2026 |
| CATX Perspective Therapeutics Buy | $2.73 | $2.88 | +5.5% | -24.9 | Open | Jan 5, 2026 |
| CGTX Cognition Therapeutics Spec buy | $1.08 | $1.04 | -3.7% | -27 | Open | Mar 9, 2026 |
| JBIO Jade Biosciences Spec buy | $17.75 | $16.94 | -4.6% | -27.2 | Open | Jun 2, 2026 |
| ATHE Alterity Therapeutics Buy | $4.15 | $3.91 | -5.8% | -27.4 | Open | Jun 10, 2026 |
| NTLA Intellia Therapeutics Spec buy | $13.20 | $12.14 | -8% | -27.5 | Open | Apr 28, 2026 |
| BBOT BridgeBio Oncology Therapeutics Spec buy | $6.75 | $4.77 | -29.4% | -27.7 | Open | Sep 9, 2026 |
| COGT Cogent Biosciences Buy | $37.00 | $31.50 | -14.9% | -28.6 | Open | Apr 20, 2026 |
| TNGX Tango Therapeutics Buy | $24.87 | $21.75 | -12.5% | -28.8 | Open | May 14, 2026 |
| RYTM Rhythm Pharmaceuticals Buy | $102.59 | $97.71 | -4.8% | -29.8 | Open | Jan 20, 2026 |
| ACRV Acrivon Therapeutics Buy | $1.93 | $1.85 | -4.1% | -30.8 | Open | Jan 8, 2026 |
| ABOS Acumen Pharmaceuticals Spec buy | $2.71 | $2.65 | -2.2% | -31.1 | Open | Mar 23, 2026 |
| CBIO Crescent Biopharma Buy | $18.52 | $15.67 | -15.4% | -31.3 | Closed Jul 15, 2026 | May 11, 2026 |
| MAIA MAIA Biotechnology Spec buy | $1.31 | $1.31 | 0% | -31.9 | Open | Mar 30, 2026 |
| ARVN Arvinas Spec buy | $10.78 | $8.14 | -24.5% | -34.6 | Closed Jun 23, 2026 | May 4, 2026 |
| ANAB AnaptysBio Spec buy | $66.59 | $55.20 | -17.1% | -34.9 | Open | Apr 27, 2026 |
| IPSC Century Therapeutics Spec buy | $2.21 | $1.86 | -15.8% | -35.1 | Open | Jun 9, 2026 |
| ELTX Elicio Therapeutics Avoid | $2.76 | $3.85 | +39.5% | -35.6 | Closed Jun 18, 2026 | Jun 16, 2026 |
| GLSI Greenwich LifeSciences Spec buy | $22.25 | $18.99 | -14.7% | -36.6 | Open | Jun 5, 2026 |
| AKBA Akebia Therapeutics Spec buy | $1.16 | $0.92 | -21% | -37.4 | Open | May 8, 2026 |
| VTVT vTv Therapeutics Spec buy | $36.41 | $31.80 | -12.7% | -37.7 | Open | Feb 4, 2026 |
| KYTX Kyverna Therapeutics Buy | $8.99 | $7.13 | -20.7% | -38.5 | Open | Apr 27, 2026 |
| GPCR Structure Therapeutics Buy | $43.56 | $35.00 | -19.7% | -39.1 | Open | Apr 28, 2026 |
| TSHA Taysha Gene Therapies Buy | $6.46 | $5.02 | -22.3% | -40.1 | Open | Apr 27, 2026 |
| CLNN Clene Buy | $5.18 | $4.35 | -16% | -42.5 | Open | Jan 12, 2026 |
| RARE Ultragenyx Pharmaceutical Buy | $24.93 | $14.51 | -41.8% | -44.2 | Open | Aug 5, 2026 |
| VKTX Viking Therapeutics Buy | $36.41 | $28.99 | -20.4% | -45.9 | Open | Dec 23, 2025 |
| GLUE Monte Rosa Therapeutics Buy | $17.50 | $12.13 | -30.7% | -46.2 | Open | Apr 14, 2026 |
| IMTX Immatics Buy | $10.45 | $8.62 | -17.5% | -46.5 | Open | Jan 2, 2026 |
| GRCE Grace Therapeutics Spec buy | $3.83 | $2.16 | -43.6% | -47.7 | Closed Apr 27, 2026 | Jan 26, 2026 |
| XENE Xenon Pharmaceuticals Buy | $57.40 | $39.75 | -30.7% | -48.1 | Open | May 4, 2026 |
| CRBU Caribou Biosciences Spec buy | $1.94 | $1.30 | -33% | -49.3 | Open | May 8, 2026 |
| CNTB Connect Biopharma Spec buy | $2.54 | $1.24 | -51.2% | -49.5 | Closed Sep 16, 2026 | Aug 13, 2026 |
| DBVT DBV Technologies Buy | $20.27 | $14.70 | -27.5% | -50 | Closed Jul 17, 2026 | Dec 22, 2025 |
| ALT Altimmune Buy | $4.09 | $3.25 | -20.5% | -51 | Open | Jan 5, 2026 |
| LRMR Larimar Therapeutics Buy | $5.23 | $3.79 | -27.5% | -51.4 | Open | Mar 2, 2026 |
| CYDY CytoDyn Spec buy | $0.32 | $0.22 | -31.2% | -54.1 | Closed Sep 1, 2026 | Apr 27, 2026 |
| VRDN Viridian Therapeutics Buy | $29.17 | $22.00 | -24.6% | -54.4 | Open | Feb 5, 2026 |
| KTTA Pasithea Therapeutics Buy | $0.77 | $0.52 | -31.9% | -54.7 | Open | May 18, 2026 |
| OCGN Ocugen Spec buy | $1.65 | $1.06 | -35.8% | -54.9 | Open | Jan 22, 2026 |
| CABA Cabaletta Bio Buy | $4.15 | $2.55 | -38.6% | -55.7 | Open | May 5, 2026 |
| IMRX Immuneering Spec buy | $6.66 | $4.48 | -32.7% | -59.7 | Open | Dec 29, 2025 |
| INAB IN8bio Spec buy | $1.56 | $0.98 | -37.2% | -60.4 | Closed Aug 7, 2026 | Jun 2, 2026 |
| NGEN NervGen Pharma Spec buy | $3.85 | $2.05 | -46.8% | -64.6 | Open | Apr 27, 2026 |
| CTMX CytomX Therapeutics Spec buy | $4.46 | $2.76 | -38.1% | -66.9 | Open | Mar 23, 2026 |
| GANX Gain Therapeutics Buy | $3.19 | $1.76 | -44.8% | -69.3 | Open | Dec 22, 2025 |
| BIOA BioAge Labs Buy | $15.34 | $8.06 | -47.5% | -70.2 | Open | May 18, 2026 |
| STRO Sutro Biopharma Buy | $33.59 | $15.34 | -54.3% | -72.1 | Open | Apr 27, 2026 |
| LXEO Lexeo Therapeutics Spec buy | $8.12 | $4.20 | -48.3% | -74.7 | Open | Jan 12, 2026 |
| TARA Protara Therapeutics Spec buy | $7.43 | $3.55 | -52.2% | -75.7 | Open | Feb 23, 2026 |
| MIST Milestone Pharmaceuticals Buy | $2.20 | $0.92 | -58.4% | -87.4 | Open | Dec 16, 2025 |
| EYPT EyePoint Buy | $13.34 | $3.85 | -71.1% | -91.3 | Open | May 1, 2026 |
| ERAS Erasca Avoid | $9.11 | $19.50 | +114.1% | -93.5 | Closed Jul 14, 2026 | Apr 29, 2026 |
| WVE Wave Life Sciences Buy | $13.44 | $4.35 | -67.6% | -94.5 | Open | Mar 3, 2026 |
| GUTS Fractyl Health Spec buy | $2.09 | $0.60 | -71.3% | -95.2 | Open | Jan 7, 2026 |
| QURE uniQure Avoid | $17.99 | $46.29 | +157.3% | -146.6 | Closed Jun 18, 2026 | Mar 9, 2026 |
| REPL Replimune Group Avoid | $1.70 | $9.00 | +429.4% | -428.3 | Closed Jun 1, 2026 | Apr 13, 2026 |
No calls match these filters.
On my watch list
- MBRX Moleculin Biotech Watch
Nasdaq delisting letter arrived on schedule with no cure period; the pre-data financing requirement, ratchet, and drifting blinded CR rate are unchanged, so the Watch stance is maintained pending a Panel decision and a financing above $0.75.
- TYRA Tyra Biosciences Watch
RA Capital's $200M add and Paradigm's new 5.8% stake confirm specialist money read the 57% CR as a dosing problem not a drug failure, strengthening the ownership leg of the thesis, but efficacy at 70 mg remains the only thing that can convert the rating.
-
Cash flows and 2035 patent floor are real, but the terminal value question — whether ORLADEYO's oral franchise survives a superior oral competitor — has a dated answer arriving in 2027, and there is no compensation for owning the uncertainty ahead of it.
-
FDA's Breakthrough Therapy Designation for daraxonrasib + GnP in 1L PDAC improves the regulatory path but supplies no new efficacy data, leaving launch execution and net pricing as the unresolved questions until the November commercial print.
- IDYA IDEAYA Biosciences Watch
Darovasertib's randomized PFS win is real but the valuation is carried by IDE849 and MTAP assets that face near-term, unproven tests in Western populations; no need to own it before Q4 2026 IDE849 readout.
- NKTR Nektar Therapeutics Watch
A data-triggered quiet period signals the REZOLVE-AA 24-week off-treatment durability read is imminent, creating an asymmetric binary where a soft result does real damage to the AA thesis while a clean result only directionally de-risks it.
- HRMY Harmony Biosciences Watch
A genuinely cheap and profitable business, but the entire franchise's remaining patent life hinges on a single pending court ruling due October 22, 2026, and at $41 the stock has priced that binary as already resolved favorably.
-
Dosing first EXACT patients retires execution risk but the S-1 converts the warrant overhang into registered sellable stock, and the efficacy case remains n=3 on a surrogate no regulator has validated.
-
Science and balance sheet are solid but the flagship TRYNGOLZA posted only $4.6M in Q2 at its new $40K price, leaving the >$3B peak-sales claim entirely unproven; wait for the Q3 print to confirm revenue inflection before opening a position.
- RNTX Rein Therapeutics Watch
The biology is real and the price is cheap, but the differentiating epithelial-regeneration mechanism has no significant human evidence, disclosure is selectively framed, and the true de-risking event is the full 120-patient RENEW Week-24 FVC dataset in 2028, not the Q4 2026 interim.
- NKTX Nkarta Watch
ACR Convergence November 8 oral slots confirmed with management signaling early efficacy, but below-cash cushion has closed at $3.23 and no lupus nephritis abstract; position is now a straight data bet.
- MGTX MeiraGTx Watch
The AQP1 mechanism is elegant and human-validated, but three of four 'pivotal' programs rest on failed, per-protocol, or compassionate-use datasets, and the fourth is 24 open-label patients on a questionnaire with no validated threshold; revisit on the AQUAx2 readout in Q2 2027, a sub-$9 print, or Hologen paying the $95M.
- PTN Palatin Technologies Watch
No named development candidate, no human data on either lead program, and the lead indication already has an approved competitor; revisit after a named candidate and Phase 1 tolerability data emerge.
- PCVX Vaxcyte Watch
Topline guidance narrowed to end-October and Pfizer's former vaccines CMO hired to lead the totality-of-evidence argument, but the binary is unchanged: OPUS-1 must still clear 0.667 on 28 serotypes with pre-announced misses, the lot-to-lot study is undated, and ACIP remains under stay.
-
Islet IND filing converts the most under-modeled asset into a company-owned registrational program, but the undisclosed Phase 3 NI margin, going-concern conclusion, and impending dilutive raise keep the stance at Watch.
- KZIA Kazia Therapeutics Watch
Pharmacodynamics are genuinely interesting but every efficacy number comes from six unblinded patients on an active backbone with one ineligible patient providing the only complete response; a control arm is needed before taking a position.
- ACET Adicet Bio Watch
Last patient visit complete and topline now guided to September 2026 with a webcast; the enrollment red flag is effectively defused, but the binary is unchanged and the free-look window has narrowed to roughly four weeks with the stock up further.
-
Safety profile and CVR structure have merit, but the drug never separated from placebo in the full randomized population, the RA pivot carries the highest placebo response rate in immunology, and the 68% counterparty (Scipher) cannot be properly evaluated until the S-4 discloses audited financials and 2026 Note conversion terms.
-
Strong randomized PFS data and unmet need are offset by a pre-specified crossover-adjusted OS analysis that came back worse than unadjusted (HR 1.13), unpublished duration of response, and an unresolved FDA meeting outcome; the author will revisit after the Labor Day FDA feedback and ESMO October 24 data.
- INSM Insmed Watch
Japan MHLW approval of BRINSUPRI is a clean de-risking of the one guided regulatory catalyst in the window, but the TPIP data gap, persistence question, and valuation are unchanged, so the watch stance is maintained.
-
First PBGENE-DMD patient dosed on schedule retires execution risk but not biology or safety risk; the HBV cure thesis still awaits NUC-withdrawal data.
- ACIU AC Immune Watch
ACI-19764 cleared first-in-human with confirmed CSF penetration, dose-dependent IL-1β inhibition, and a 4x lower-than-predicted therapeutic dose, upgrading the second shot on goal, but VacSYn week-100 remains the decisive catalyst and no owned asset has efficacy data.
-
Strong biology and productive platform, but Lineage owns only ~half the economics of a lead asset it does not control on a timeline it cannot influence; revisit only on Roche's public disclosure of intent to advance OpRegen into a controlled multicenter Phase 2/3.
-
The $150M ATM bridges the structural dilution gap and de-links launch spending from the approval-triggered warrant clock, but the Sopharma arbitration and NCE exclusivity question remain unresolved, keeping the stock uninvestable.
- KOD Kodiak Sciences Hold
Cash down to $125.9M with going-concern language still present and burn accelerating as a third Phase 3 (ALTO) launches; a capital raise is the most predictable unannounced event on the calendar, and DAYBREAK in September gates everything — BLA, platform thesis, and financing terms.
- GNLX Genelux Watch
Q2 burn accelerated to $9.6M against $18.7M total cash with the Phase 3 topline still guided to 2H 2026, tightening the runway squeeze but leaving the scientific thesis and watch-list stance unchanged.
-
Science unchanged but funding quality weakened — burn not moderating at ~$70M/quarter, ATM issuance tripling, and IP pledged as collateral on Hercules debt; thesis still resolves at Q2 2027 4FRONT-1 readout.
- EIKN Eikon Therapeutics Watch
Resolution of the Seven and Eight licensor dispute removes a key tail risk, but accelerating burn (77% YoY) widens the dilution gap and no efficacy data has changed; the randomized melanoma interim remains the sole re-rating trigger.
-
WATCH maintained with downgraded urgency as 39.6M warrants at $2.65 are now exercisable creating a structural ceiling, NDA slipped to mid-2027, and another financing raise is likely before the key catalyst.
- SCYX Scynexis Watch
Adage Capital's 9.99% filing narrows the sponsorship gap in the bear case, but with ~half the position in deep-OTM warrants and no human ADPKD efficacy, the stance remains Watch with piqued interest.
- ANNX Annexon Watch
ARCHER II adds Month 24 dual primary endpoint meaning Q4 2026 delivers only a DMC verdict with full data potentially in Q1 2027; catalyst diffusion and $117.8M ATM overhead keep the stock on watch despite improved GBS outlook and runway extended into 2028.
- ZURA Zura Bio Watch
Naming PMR as the third indication — where both IL-17 and B-cell arms have randomized clinical support — narrows the bear case modestly, but the BAFF contribution in HS remains unproven and Q4 2026 remains a binary with the stock more than tripled off its lows.
-
REGAL still at 78/80 events after three months of silence; readout timing now indefinite; stock at $11 with doubled downside risk vs. May; fortress balance sheet intact but premium for the binary has a time cost; watch for existing holders to consider trimming.
-
IZAR-1 Phase 3 win de-risks the PsA franchise but the de-risking event remains the Section 14 label content at BLA acceptance in late November 2026; the blinded placebo arm keeps the PsA delta unpriceable.
- IMUX Immunic Watch
Watch list maintained as runway is now explicitly bridged to late 2027 and the commercial/regulatory team is complete, but fenebrutinib, generic Aubagio, the 5% royalty stack, and dilution overhang are unchanged, and the stock at $15.48 has compressed the pre-data asymmetry considerably.
- IMNM Immunome Watch
FDA acceptance with April 2027 PDUFA date is procedurally de-risking but EV expanded to ~$2.5B on a standard review timeline, stretching valuation further while commercial risk is time-amplified by nine more months of incumbent entrenchment.
- BCAX Bicara Therapeutics Watch
Balance sheet, trial, and M&A logic remain intact and PTAB institution improves the patent overhang picture, but efficacy case is still single-arm open-label and leadership bench will be substantially new by the time the interim prints.
- RLAY Relay Therapeutics Watch
The mechanism is de-risked and the chemistry is elite, but at ~$4.35B market cap the risk/reward has already been harvested on 57- and 20-patient open-label cohorts with managed denominators; revisit on the YE2026 vascular anomaly regulatory update or a ReDiscover-2 enrollment-completion announcement.
-
Both Alzheimer's catalysts pushed to Q4 2026, VY1706 first human safety data slipped to early 2027, ATM tapped into weakness at ~$3.61, and cash down to $148.8M; proxy waiting game extended.
-
Second IDMC pass at 80% exposure meaningfully reduces the safety tail and extends runway to Q1 2029, but the central PVR→6MWD scientific bet remains unresolved and the relaxin graveyard still demands humility ahead of the APEX binary.
-
Phase 3 initiation slipped from mid-2026 to upon IND clearance due to CMC manufacturing delays, funding language softened, and no efficacy readout is expected in the next twelve months; Watch List maintained with clock reset as the next event is an IND filing, not data.
- INMB Inmune Bio Watch
Q2 brought competent execution and improved catalyst clarity (US BLA now on calendar for Q1 2027) but neither named de-risker has landed — the going-concern flag remains and the MHRA MAA submission is still ahead — so the watch stance is maintained.
- INKT MiNK Therapeutics Watch
Encouraging early safety and biomarker data from C-1300-02 are positive but uncontrolled; the binary randomized readout has slipped to early 2027, adding two quarters of dilution risk with no change in the fundamental concerns that kept this off a Buy.
-
Watch List maintained as the CBP degrader IND timeline was withdrawn due to a CRO operational failure, weakening the wholly-owned pipeline leg, while FHD-909 remains a Lilly-controlled black box with no human efficacy data or readout date.
-
Cash fell to $45.1M, new FDRR language signals FDA dialogue is not converging, pipeline initiations are unfunded and overdue, but AbbVie option remains alive and burn discipline extends the optionality runway.
- PALI Palisade Bio Watch
Prodrug engineering is real and balance sheet funds the binary, but PDE4 failed its one controlled UC trial, Phase 2 doses are below the regimen that generated the clinical signal, and there is no issued U.S. patent under a ~$457M market cap.
- NAMS NewAmsterdam Pharma Watch
Q2 update confirms balance sheet intact and EU approval advancing, but no U.S. NDA date disclosed and the single binary DSMB recommendation in Q1 2027 remains the only thing that matters for the U.S. thesis.
- TGTX Tg Therapeutics Watch
Q2 beat and second guidance raise validate the commercial thesis, but at $46.17 — above the prior 52-week high — the easy entry has closed and the year-end SubQ Phase 3 topline remains the event worth sizing around.
- ANIX Anixa Biosciences Watch
FSHR biology is real but no objective response in four years, survival benchmark is misstated, and capital structure risks are material; wait for RECIST-confirmed responses from therapeutic-dose cohorts 5–7.
- ENTX Entera Bio Watch
Despite a de-risked mechanism and strong balance sheet post-financing, the 21-patient efficacy signal, untested Phase 3 dose, primary endpoint outside FDA's qualified 24-month context of use, and 85% post-financing markup into a 26-month catalyst desert make this the wrong entry at the wrong price.
- CGEN Compugen Watch
Near-cash EV with partnered Phase 3 royalty and Gilead option provides cushion, but the owned binary (COM701 monotherapy maintenance) rests on a post-hoc subgroup and thin single-agent data in a distrusted checkpoint class, warranting a watch rather than an immediate buy.
The full record
| Category | # calls | Beat XBI | Avg return | Avg vs XBI |
|---|---|---|---|---|
| Open buy calls | 137 | 36% | +8.6% | -6.2 |
| Core | 62 | 37% | +13% | -6.7 |
| Speculative | 75 | 35% | +4.9% | -5.7 |
| Open avoid calls | 20 | 80% | — | +31.5 |
| Closed buy calls | 20 | 30% | +8.7% | -3.5 |
| Closed avoids | 15 | 60% | — | -29.2 |
Hypothetical editorial track record, not a managed portfolio — past performance does not guarantee future results. Not investment advice.